The pharmaceutical group Sanofi announced Monday that it has received authorization to market in the United States Sarclisa, a monoclonal antibody, to fight in combination with other treatments against certain forms of multiple myeloma.
Read also: Sanofi: unions denounce the creation of a subsidiary for active ingredients
The Food and drug administration (FDA), American drug agency, " approved Sarclisa (...) in the treatment of relapsed or refractory multiple myeloma ", in combination with pomalidomide and dexamethasone, said the group in a statement. The decision was made on the basis of a clinical trial that demonstrated " statistically significant improvement " in patient survival, adds Sanofi.
Multiple myeloma is a form of cancer of the plasma cells, caused by abnormal production of cells inside the plasma, which multiply and accumulate in the bone marrow, crowding out healthy cells while preventing them from functioning normally. .
Multiple myeloma is the second hematologic cancer in terms of frequency, and affects more than 130,000 patients in the United States, where nearly 32,000 new cases are diagnosed each year. Despite the treatments available, multiple myeloma is incurable.
